Price
CHART BY
Frequently asked questions
What is OmniAb's market capitalization?
The market capitalization of OmniAb is $432.02M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for OmniAb?
OmniAb's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$0.623. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for OmniAb's stock?
Currently, 8 analysts cover OmniAb's stock, with a consensus target price of $9.625. Analyst ratings provide insights into the stock's expected performance.
What is OmniAb's revenue over the trailing twelve months?
Over the trailing twelve months, OmniAb reported a revenue of $20.41M.
What is the EBITDA for OmniAb?
OmniAb's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$61.30M. EBITDA measures the company's overall financial performance.
What is the free cash flow of OmniAb?
OmniAb has a free cash flow of -$46.85M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does OmniAb have, and what sector and industry does it belong to?
OmniAb employs approximately 106 people. It operates in the Health Care sector, specifically within the Miscellaneous Commercial Services industry.
What is the free float of OmniAb's shares?
The free float of OmniAb is 97.86M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $432.02M
- EPS (TTM)
- -$0.623
- Free Float
- 97.86M
- Revenue (TTM)
- $20.41M
- EBITDA (TTM)
- -$61.30M
- Free Cashflow (TTM)
- -$46.85M
Pricing
- 52W span
- $3.43$6.54
Analyst Ratings
The price target is $9.625 and the stock is covered by 8 analysts.
Buy
8
Hold
0
Sell
0
Information
OmniAb, Inc. operates as a drug discovery company. It focuses on developing human monoclonal and bispecific therapeutic antibodies. Its platform includes the biological intelligence of its transgenic animals, including OmniRat, OmniChicken and OmniMouse. The company was founded on December 14, 2015 and is headquartered in Emeryville, CA.
- Employees
- 106
- Industries
- Miscellaneous Commercial Services
- Sector
- Health Care
Identifier
- ISIN
- US68218J1034
- Primary Ticker
- OABI